Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10335390 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US11000507 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US11020377 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US11000508 | LUPIN | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(12 years from now) | |
US10682338 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US10849884 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US10857133 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US11324721 | LUPIN | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(12 years from now) | |
US11602522 | LUPIN | Secnidazole for use in the treatment of sexually transmitted infection |
Sep, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 15, 2022 |
New Indication (I) | Jun 30, 2024 |
New Patient Population (NPP) | Jan 26, 2025 |
Generating Antibiotic Incentives Now (GAIN) | Sep 15, 2027 |
NCE-1 date: 2026-09-15
Market Authorisation Date: 15 September, 2017
Treatment: Treatment of bacterial vaginosis in adult women; Treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of trichomoniasis in patients 12 years of age and older; Treat...
Dosage: GRANULE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic